Get the Stockscreener App
4.6707
0.64%
-0.0293
Aptevo Therapeutics Inc stock is traded at $4.6707, with a volume of 57,388.
It is down -0.64% in the last 24 hours and down -55.94% over the past month.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
See More
Previous Close:
$4.70
Open:
$4.59
24h Volume:
57,388
Relative Volume:
0.24
Market Cap:
$3.18M
Revenue:
$12.99M
Net Income/Loss:
$-23.72M
P/E Ratio:
-0.048
EPS:
-97.2514
Net Cash Flow:
$-23.28M
1W Performance:
-15.21%
1M Performance:
-55.94%
6M Performance:
-97.75%
1Y Performance:
-99.13%
1-Day Range:
$4.5308
$4.9299
1-Week Range:
$4.30
$5.50
52-Week Range:
$4.30
$658.60
Aptevo Therapeutics Inc Stock (APVO) Company Profile
Name
Aptevo Therapeutics Inc
Sector
Industry
Phone
206-838-0500
Address
2401 4TH AVE., SEATTLE, WA
Compare APVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APVO
Aptevo Therapeutics Inc
|
4.67 | 121.64K | 12.99M | -23.72M | -23.28M | -97.25 |
|
ONC
Beone Medicines Ltd Adr
|
247.37 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.61 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.42 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
491.16 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-18 | Initiated | Ladenburg Thalmann | Buy |
| Oct-05-17 | Resumed | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc Stock (APVO) Latest News
Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Large Decrease in Short Interest - Defense World
Aptevo Therapeutics (APVO) Trading Suspended as News Awaits | AP - GuruFocus
Aptevo Therapeutics (APVO) Trading Suspended as News Awaits | APVO Stock News - GuruFocus
Aptevo Therapeutics Approves 1-for-20 Reverse Stock Split - TipRanks
Aptevo Therapeutics Announces Reverse Stock Split - TipRanks
Aptevo Therapeutics to Implement 1-for-20 Reverse Stock Split - marketscreener.com
Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as pa - GuruFocus
Aptevo Therapeutics (APVO) Announces 1-for-20 Reverse Stock Split | APVO Stock News - GuruFocus
Aptevo Therapeutics enacts reverse stock split to maintain Nasdaq compliance - Investing.com
Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan - ACCESS Newswire
Aptevo's Dramatic 1:20 Reverse Split Cuts Shares from 13.5M to 0.7M in Nasdaq Compliance Push - Stock Titan
StockNews.com Begins Coverage on Aptevo Therapeutics (NASDAQ:APVO) - Defense World
Aptevo Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Aptevo reports high remission in AML patients with new drug By Investing.com - Investing.com South Africa
APVO: Promising Trial Results Propel AML Treatment Innovations | - GuruFocus
APVO: Promising Trial Results Propel AML Treatment Innovations | APVO Stock News - GuruFocus
Aptevo reports high remission in AML patients with new drug - Investing.com Australia
Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig | APVO Stock News - GuruFocus
Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig - ACCESS Newswire
Breakthrough: New AML Drug Shows 90% Remission Rate With Zero Cytokine Release Syndrome - Stock Titan
Aptevo Therapeutics (APVO) Expected to Announce Earnings on Wednesday - Defense World
Aptevo Therapeutics (NASDAQ:APVO) Now Covered by Analysts at StockNews.com - Defense World
Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules - ACCESS Newswire
Aptevo Therapeutics Provides Program Update for Bispecific APVO7 - GuruFocus
Aptevo Therapeutics Says In Preclinical Studies APVO711 Demonstrates Dual Anti-Cancer Functionality - marketscreener.com
Aptevo Therapeutics (APVO) Advances Innovative Immunotherapy wit - GuruFocus
Aptevo Therapeutics (APVO) Advances Innovative Immunotherapy with APVO711 Update | APVO Stock News - GuruFocus
Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation | APVO Stock News - GuruFocus
Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation - ACCESS Newswire
Aptevo Therapeutics announces common stock offering - Investing.com Australia
APVO’s latest rating updates from top analysts. - knoxdaily.com
Strategic Moves Drive Stock Gains For OSR, Lianhe Sowell, And Aptevo - Finimize
Aptevo Therapeutics announces common stock offering By Investing.com - Investing.com Canada
Closing Bell Recap: Aptevo Therapeutics Inc (APVO) Ends at 0.61, Reflecting a -9.31 Downturn - DWinneX
Aptevo Therapeutics announces at-the-market offering - Investing.com Australia
APVO stock plunges to 52-week low, touches $0.59 - Investing.com
APVO stock plunges to 52-week low, touches $0.59 By Investing.com - Investing.com UK
Aptevo Therapeutics announces at-the-market offering By Investing.com - Investing.com India
SEC Form 424B4 filed by Aptevo Therapeutics Inc. - Quantisnow
Press Release Distribution & PR Platform - ACCESS Newswire
Aptevo Therapeutics Inc. Announces Pricing of $5 Million Public Offering - ACCESS Newswire
Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds - ACCESS Newswire
Applied Materials Q2 Earnings: Tech Giant's Financial Results Coming May 15 - Stock Titan
A look into Aptevo Therapeutics Inc (APVO)’s deeper side - Sete News
Aptevo Therapeutics Inc’s latest rating changes from various analysts - knoxdaily.com
Evogene (EVGN) Sees Dramatic Surge in Investor Interest Amid Strategic Moves | APVO Stock News - GuruFocus
Market Momentum: Aptevo Therapeutics Inc (APVO) Registers a 9.08 Increase, Closing at 0.69 - DWinneX
Aptevo Therapeutics Inc Stock (APVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):